StreetInsider.com News Articles

aTyr Pharma partners with Montefiore Einstein on bone cancer research

Mon, 19 Oct 2026 07:04:04 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) announced a research collaboration with Albert Einstein College of Medicine to study ATYR2810, its monoclonal antibody targeting the neuropilin-2 (NRP2) receptor, in pediatric bone cancers.

The collaboration will be led by Bang H. Hoang, M.D., Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology at Montefiore Einstein, whose research focuses on the molecular mechanisms of bone and soft tissue cancer, including the role of NRP2 in pediatric osteosarcoma.

"Aggressive solid tumors like osteosarcoma present a profound therapeutic challenge due to an immunosuppressive microenvironment. By selectively blocking the NRP2 signaling pathway, ATYR2810 is designed to disrupt myeloid-driven

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

Mon, 19 Oct 2026 07:00:00 -0400

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810, the Company’s monoclonal antibody that targets the neuropilin-2 (NRP2) receptor. The collaboration will be led by Bang H. Hoang, M.D., Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology in the Department of Orthopaedic Surgery at Montefiore Einstein. Dr. Hoang’s

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

Mon, 19 Oct 2026 07:00:00 -0400

Form 8-K aTYR PHARMA INC For: Oct 16

Fri, 16 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261016/27197917.html

aTyr Pharma publishes anti-fibrotic findings for ATYR0101

Tue, 13 Oct 2026 08:04:59 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) announced the publication of research demonstrating anti-fibrotic effects of its drug candidate ATYR0101 in the Journal of Biological Chemistry, according to a company statement dated Oct. 13, 2026.

The paper, titled "Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to Abrogate Tissue Fibrosis," describes how ATYR0101, a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS), binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to selectively trigger apoptosis in myofibroblasts, cells associated with tissue scarring.

The publication details results from an in vivo bleomycin lung model of fibrosis, in which ATYR0101 showed a

aTyr Pharma publishes anti-fibrotic findings for ATYR0101

Tue, 13 Oct 2026 08:04:59 -0400

The publication details results from an in vivo bleomycin lung model of fibrosis, in which ATYR0101 showed a

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

Tue, 13 Oct 2026 08:00:00 -0400

Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.

ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027.

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. The publication, entitled, “Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

Tue, 13 Oct 2026 08:00:00 -0400

Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.

ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027.

Form SCHEDULE 13G/A aTYR PHARMA INC Filed by: FEDERATED HERMES, INC.

Wed, 07 Oct 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20261007/27157945.html

Form 4 aTYR PHARMA INC For: Oct 01 Filed by: Yaras Brandon

Thu, 01 Oct 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20261001/27135796.html

Form 3 aTYR PHARMA INC For: Oct 01 Filed by: Yaras Brandon

Thu, 01 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261001/27135759.html

Form 8-K aTYR PHARMA INC For: Sep 24

Thu, 24 Sep 2026 07:47:00 -0400

si-local-file:///var/storage/secattach/20260924/27098930.html

aTyr Pharma reaches FDA alignment on Phase 3 efzofitimod study

Thu, 24 Sep 2026 06:00:50 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) announced it has reached alignment with the U.S. Food and Drug Administration on the protocol for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, according to a press release.

The company expects to initiate study-related activities in the fourth quarter of 2026, with a focus on regulatory submissions in the U.S. and Europe.

The planned trial will be a global, randomized, double-blind, placebo-controlled study enrolling up to approximately 372 patients. The 54-week study will include two parallel cohorts receiving either 5.0 mg/kg efzofitimod or placebo administered intravenously once

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Thu, 24 Sep 2026 06:00:00 -0400

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.

Company expects to initiate study-related activities in the fourth quarter of 2026.

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Thu, 24 Sep 2026 06:00:00 -0400

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.

Company expects to initiate study-related activities in the fourth quarter of 2026.

Form DEF 14A aTYR PHARMA INC For: Oct 16

Fri, 11 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260911/27052923.html

aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept

Tue, 01 Sep 2026 16:39:05 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) said it expects to receive a response from the U.S. Food and Drug Administration by mid-September 2026 regarding a protocol the company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

The planned Phase 3 trial is designed as a global, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study would enroll up to approximately 372 patients across two parallel cohorts, randomized equally to receive either 5.0 mg/kg efzofitimod

aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept

Tue, 01 Sep 2026 16:39:05 -0400

aTyr Pharma, Inc. (ATYR) Tops Q2 EPS by 1c

Mon, 10 Aug 2026 06:00:22 -0400

aTyr Pharma, Inc. (NASDAQ: ATYR) reported Q2 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12).

For earnings history and earnings-related data on aTyr Pharma, Inc. (ATYR) click here.

Form S-8 aTYR PHARMA INC

Fri, 07 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26891104.html

Form S-8 aTYR PHARMA INC

Fri, 07 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26891104.html

Form 10-Q aTYR PHARMA INC For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891054.html

Form 10-Q aTYR PHARMA INC For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891054.html

Form 8-K aTYR PHARMA INC For: Aug 07

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890932.html

Form 8-K aTYR PHARMA INC For: Aug 07

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890932.html